Neuraxpharm has broken ground in the Middle East, launching a dedicated operation covering the six member states of the Gulf Cooperation Council as the company continues its international expansion.
The company’s Neuraxpharm Middle East operation comprises the Kingdom of Saudi Arabia, the United Arab Emirates, Bahrain, Kuwait, Oman and Qatar, marking the next step in Neuraxpharm’s plans to make the anti-CD20 antibody Briumvi (ublituximab) for relapsing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?